Abstract
Balanol, a fungal metabolite, is a potent ATP-competitive inhibitor of Protein Kinase C (PKC) and Protein Kinase A (PKA), important targets in oncology. Since its discovery in 1993, a number of studies have been performed in order to design selective and bioavailable balanol analogs. Several crystal structures of PKA in complex with balanol and a few analogs bound within the catalytic site have also been solved providing insight about the key interactions for binding. The PKA-balanol complex has also served as an interesting model system for structurebased ligand design and validation of a number of computational methodologies aimed at both understanding the physical basis for molecular recognition and addressing the important issue of protein flexibility in ligand binding. We provide an overview of the structure-activity relationships of balanol analogs and summarize the progress made in structural and computational studies involving balanol.
Keywords: Balanol, structure activity relationships, kinases, computational chemistry, x-ray crystal structure, protein flexibility, adenosine triphosphate
Anti-Cancer Agents in Medicinal Chemistry
Title: The Protein Kinase Inhibitor Balanol: Structure – Activity Relationships and Structure-Based Computational Studies
Volume: 8 Issue: 6
Author(s): Vineet Pande, Maria J. Ramos and Federico Gago
Affiliation:
Keywords: Balanol, structure activity relationships, kinases, computational chemistry, x-ray crystal structure, protein flexibility, adenosine triphosphate
Abstract: Balanol, a fungal metabolite, is a potent ATP-competitive inhibitor of Protein Kinase C (PKC) and Protein Kinase A (PKA), important targets in oncology. Since its discovery in 1993, a number of studies have been performed in order to design selective and bioavailable balanol analogs. Several crystal structures of PKA in complex with balanol and a few analogs bound within the catalytic site have also been solved providing insight about the key interactions for binding. The PKA-balanol complex has also served as an interesting model system for structurebased ligand design and validation of a number of computational methodologies aimed at both understanding the physical basis for molecular recognition and addressing the important issue of protein flexibility in ligand binding. We provide an overview of the structure-activity relationships of balanol analogs and summarize the progress made in structural and computational studies involving balanol.
Export Options
About this article
Cite this article as:
Pande Vineet, Ramos J. Maria and Gago Federico, The Protein Kinase Inhibitor Balanol: Structure – Activity Relationships and Structure-Based Computational Studies, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (6) . https://dx.doi.org/10.2174/187152008785133056
DOI https://dx.doi.org/10.2174/187152008785133056 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of Charge Transfer Reactions for the Quantitative Spectrophotometric Determination of Cyclophosphamide in Pure and Pharmaceutical Formulation
Current Pharmaceutical Analysis Meningioma in an Elderly Presenting as Psychosis: A Case Report
Clinical Cancer Drugs Different Gene Therapy Strategies: A Overview for Prostate Cancer
Current Gene Therapy Deacetylase Inhibitors Modulate the Myostatin/Follistatin Axis without Improving Cachexia in Tumor-Bearing Mice
Current Cancer Drug Targets Clinical Management of Secretion Retention in Critically Ill Patients who are Intubated and Mechanically Ventilated
Current Respiratory Medicine Reviews Targeting the Secretory Pathway for Anti-Inflammatory Drug Development
Current Topics in Medicinal Chemistry Potential Utilization of Bystander / Abscopal-Mediated Signal Transduction Events in the Treatment of Solid Tumors
Current Signal Transduction Therapy Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry The Medicinal Chemistry of Therapeutic Peptides: Recent Developments in Synthesis and Design Optimizations
Current Medicinal Chemistry Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease
Current Medicinal Chemistry Effect of Altered WIG-1 Expression on DDP Sensitivity in a DDPResistant Esophageal Squamous Cancer Cell Line
Current Cancer Drug Targets Natural and Synthetic Furanocoumarins as Treatment for Vitiligo and Psoriasis
Current Drug Therapy Epidermal Growth Factor Receptor as a Target for Anti-Cancer Agent Design
Anti-Cancer Agents in Medicinal Chemistry Current Status of Magnetite-Based Core@Shell Structures for Diagnosis and Therapy in Oncology Short running title: Biomedical Applications of Magnetite@Shell Structures
Current Pharmaceutical Design Microwave-Assisted Synthesis of Imido-Substituted 2-Chloro-1,4-naphthoquinone Derivatives and their Cytotoxic Activities on Three Human Prostate Cancer Cell Lines
Letters in Drug Design & Discovery GH-Inhibitory Activity of Novel Somatostatin Agonists: Potential Applications in Acromegaly
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Patent Selections
Recent Patents on Biotechnology Molecular Determinants of Gastrointestinal and Liver Cancers: Role of Bile Acid Activated Nuclear Receptors
Current Topics in Medicinal Chemistry Environmental Factors and Hypertension
Current Pharmaceutical Design Advances in Biomarker Research for Pancreatic Cancer
Current Pharmaceutical Design